RxDoctor Payments Data

Guido Macchiavello, MD

Internal Medicine · New York, NYNPI 1912191347

Payments from drug & device makers

$3,897in general payments, 2019–2025

Across 149 payments — averaging $26.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AstraZeneca$417
  • Novartis$408
  • Lilly USA, LLC$321
  • Amgen$309
  • Biohaven Pharmaceutical Holding Company Ltd.$218
  • plus $1K from 14 others

What the payments were for

  • Food & beverage$3,897100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,897 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$4,125
Medicare patients
28
Services billed
39

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide109$128,249
JardianceEmpagliflozin105$98,685
JanuviaSitagliptin Phosphate82$57,022
OzempicSemaglutide43$42,947
FarxigaDapagliflozin Propanediol55$39,560
RybelsusSemaglutide23$33,142
EliquisApixaban30$24,744
Breo ElliptaFluticasone/Vilanterol49$19,078
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate12$14,205
Incruse ElliptaUmeclidinium Bromide36$12,211
RestasisCyclosporine16$11,112
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog30$11,032
Tresiba Flextouch U-200Insulin Degludec15$10,901
SymbicortBudesonide/Formoterol Fumarate42$9,270
Soliqua 100-33Insulin Glargine/Lixisenatide20$9,011

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$321$128,249109 claims
Novo NordiskOzempic, Rybelsus$1,079$76,09066 claims
MerckJanuvia, Steglujan$29$65,31794 claims
AstraZenecaFarxiga, Symbicort$417$48,83097 claims
GSKBreo Ellipta, Incruse Ellipta, Shingrix$125$35,400109 claims
PfizerEliquis$88$24,74430 claims
AbbVieRestasis, Lumigan$145$16,36330 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$46$9,01120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →